Neurogene Inc. NGNE 深 沪
已收盘 05-08 16:00:00 美东时间
30.78
-0.480
-1.54%
华盛通- 最 高31.84
- 今 开30.47
- 成交量 16.87万股
- 最 低 29.63
- 昨 收 31.26
- 总市值 4.81亿
- 52周最高 37.2659
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 14.65
- 委 比 0.00%
- 总股本 1561.58万
- 历史最高 362.60
- 量 比 0.94
- 振 幅 7.07%
- 历史最低 6.875
- 每 手 1
- 风险率 4.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 目标价31美元，潜在涨幅64%！多家大行首予PayPay"买入"评级； 大摩上调希捷科技目标价从468美元升至582美元
今日重点评级关注：Canaccord Genuity：维持Taysha Gene Therapies"买入"评级，目标价从14美元升至17美元；Guggenheim：维持天演药业"买入"评级，目标价从9美元升至10美元
04-07 11:53
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $200 to $180.
04-06 23:13
Neurogene shares are trading higher. The company reported Q4 financial results.
Neurogene shares are trading higher. The company reported Q4 financial results.
03-26 00:09
Neurogene Q4 EPS $(1.13), Inline
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.13) per share which met the analyst consensus estimate. This is a 13 percent decrease over losses of $(1.00) per share from the same period last year.
03-24 19:39
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday
Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gainers include AAOI, NGNE, ARLO, PRAA, BYND, BWIN, PSKY, & DELL.
02-28 01:52
Neurogene shares are trading higher after the company announced that the FDA granted Breakthrough Therapy designation to NGN-401.
Neurogene shares are trading higher after the company announced that the FDA gr...
02-27 05:56
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
LifeSci Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $50
LifeSci Capital analyst Patrick Dolezal initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $50.
01-26 21:45
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
